Status:
UNKNOWN
Efficacy Study of Chemotherapy to Treat Advanced or Recurrent Endometrial Cancer
Lead Sponsor:
Asan Medical Center
Collaborating Sponsors:
Boryung Pharmaceutical Co., Ltd
Conditions:
Advanced or Recurrent Endometrial Cancer
Eligibility:
FEMALE
20-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. Docetaxel ...
Eligibility Criteria
Inclusion
- Histologically confirmed chemotherapy naïve endometrial cancer
- One of following histology Endometrioid, UPSC, CCCa, squamous, adenosquamous, mixed
- FIGO stage IVb or recurrent endometrial cancer (incurable by surgery and/or RT)
- At least one measurable lesion by RECIST on CT
- ECOG PS: 0-2
- Age: 20-75
- Adequate organ function BM: ANC≥1,000/mm3, Plt≥100X103/mm3 Kidney: Creatinine\<1.25 × UNL이고, GFR ≥ 60 Liver: AST, ALT\< 3×UNL, T- bil\<1.5 mg/ mm3
- Informed Consent
- Contraception during study period
Exclusion
- Previous chemotherapy
- RT, hormone therapy, or immunotherapy within 1 month
- Other malignant disease
- Uncontrolled medical disease
- Infection requiring antibiotics
- Symptomatic CHF, RF, Angina, Arrhythmia, etc.
- Neurosis or psychosis
- Pregnancy, breast-feeding
- Etc.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
59 Patients enrolled
Trial Details
Trial ID
NCT01461759
Start Date
October 1 2011
End Date
December 1 2017
Last Update
May 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan Medical Center
Seoul, South Korea, 138-736